Moderna players, with IBM setting A.I. and quantum computing working on mRNA technology in vaccines

April 21, 2023: Moderna and IBM are collaborating to use generative artificial intelligence and quantum computing, advancing mRNA technology, the development at the core of the firm’s blockbuster Covid vaccine, the firm announced on Thursday.

“We are excited to be in with IBM to develop novel A.I. models to advance mRNA science, which prepares us for the era of quantum computing, and ready our firm for these game-changing technologies,” Moderna CEO Stephane Bancel stated.

Moderna shares dipped Thursday, while IBM’s stock was regarding flat.

The companies said they signed a deal for Moderna to access IBM’s quantum systems. According to Dr Dario Gil, IBM research director, those systems could accelerate Moderna’s discovery and creation of the recent messenger RNA vaccines and therapies.

The companies added that IBM would also provide experts who can help Moderna scientists use quantum technologies, unlike traditional computers, which store information as either zero that permits those systems to solve problems too complex for today’s computers.

Under the deal, Moderna’s scientists will have access to IBM’s generative A.I. model known as MoLFormer. Generative A.I. describes algorithms that can be used to create recent content based on the data they have been trained on.

The companies stated that Moderna would use IBM’s model to understand “the characteristics of the mRNA medicines” and design a recent class of vaccines and therapies.

The deal starts as Moderna navigates its post-pandemic boom driven by its mRNA Covid vaccine.

The Cambridge, Massachusetts-based company is a household name for its messenger RNA technology. It teaches human cells to produce a protein that initiates an immune response against a particular disease.

Moderna tries to harness that technology to target different diseases as the world emerges from the coronavirus and demand for blockbuster Covid vaccines and treatments slows.

The company is already developing a vaccine targeting the respiratory syncytial virus and a shot that can target different types of cancer combined with Merck’s immunotherapy Keytruda.

Editor's Choice

Posts You Might Like

Leave us a message


Fill the form our team will contact you

Advertise with us

Fill the form our team will contact you​